查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530970

去活化疫苗市場 - 2024-2034 年全球產業分析、規模、佔有率、成長、趨勢與預測

Inactivated Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 167 Pages | 商品交期: 2-10個工作天內

價格

去活化疫苗市場 - 報告範圍

TMR 關於全球去活化疫苗市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。年期間，考慮2024年為基準年，2034年為預測年。報告也提供了2024年至2034年全球去活化疫苗市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解去活化疫苗市場。

市場概況
2023年市場價值 406 億美元
2034 年市場價值 748 億美元
複合年成長率 5.7%

該報告深入探討了全球去活化疫苗市場的競爭格局。全球去活化疫苗市場的主要參與者已經確定，並對每個參與者的不同屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球去活化疫苗市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依疫苗類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疫苗類型，2020-2034
    • 病毒疫苗
    • 細菌疫苗
  • 市場吸引力：按疫苗類型

第 7 章：全球市場分析與預測：按去活化方法

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按失活方法，2020-2034年
    • 溶劑洗滌法
    • 輻射法
    • pH值濃度
    • 其他（熱去活化等）
  • 市場吸引力：按失活方法

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2020-2034年
    • 口服
    • 皮下
    • 靜脈
  • 市場吸引力：依給藥途徑分類

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020-2034
    • 醫院
    • 專科診所
    • 家庭護理設置
    • 其他（研究中心等）
  • 市場吸引力：按最終用戶分類

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • GSK plc
    • Novartis AG
    • Mylan NV
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Bharat Biotech
    • Serum Institute of India
    • INOVIO Pharmaceuticals, Inc.
Product Code: TMRGL31316

Inactivated Vaccines Market - Scope of Report

TMR's report on the global inactivated vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global inactivated vaccines market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inactivated vaccines market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the inactivated vaccines market.

Market Snapshot
Market Value in 2023US$ 40.6 Bn
Market Value in 2034US$ 74.8 Bn
CAGR5.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inactivated vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global inactivated vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inactivated vaccines market.

The report delves into the competitive landscape of the global inactivated vaccines market. Key players operating in the global inactivated vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global inactivated vaccines market profiled in this report.

Key Questions Answered in Global inactivated vaccines Market Report:

  • What is the sales/revenue generated by inactivated vaccines across all regions during the forecast period?
  • What are the opportunities in the global inactivated vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Inactivated Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global inactivated vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global inactivated vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global inactivated vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Inactivated Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine Type, 2020-2034
    • 6.3.1. Viral Vaccine
    • 6.3.2. Bacterial Vaccine
  • 6.4. Market Attractiveness, by Vaccine Type

7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 7.3.1. Solvent Detergent Method
    • 7.3.2. Radiation Method
    • 7.3.3. pH Concentration
    • 7.3.4. Others (Heat Inactivation, etc.)
  • 7.4. Market Attractiveness, by Method of Inactivation

8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Subcutaneous
    • 8.3.3. Intravenous
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Homecare Settings
    • 9.3.4. Others (Research Centers, etc.)
  • 9.4. Market Attractiveness, by End-user

10. Global Inactivated Vaccines Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Inactivated Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 11.2.1. Viral Vaccine
    • 11.2.2. Bacterial Vaccine
  • 11.3. Market Attractiveness, by Vaccine Type
  • 11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 11.4.1. Solvent Detergent Method
    • 11.4.2. Radiation Method
    • 11.4.3. pH Concentration
    • 11.4.4. Others (Heat Inactivation, etc.)
  • 11.5. Market Attractiveness, by Method of Inactivation
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Subcutaneous
    • 11.6.3. Intravenous
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Homecare Settings
    • 11.8.4. Others (Research Centers, etc.)
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Vaccine Type
    • 11.11.2. By Method of Inactivation
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Inactivated Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 12.2.1. Viral Vaccine
    • 12.2.2. Bacterial Vaccine
  • 12.3. Market Attractiveness, by Vaccine Type
  • 12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 12.4.1. Solvent Detergent Method
    • 12.4.2. Radiation Method
    • 12.4.3. pH Concentration
    • 12.4.4. Others (Heat Inactivation, etc.)
  • 12.5. Market Attractiveness, by Method of Inactivation
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Subcutaneous
    • 12.6.3. Intravenous
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Homecare Settings
    • 12.8.4. Others (Research Centers, etc.)
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Vaccine Type
    • 12.11.2. By Method of Inactivation
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 13.2.1. Viral Vaccine
    • 13.2.2. Bacterial Vaccine
  • 13.3. Market Attractiveness, by Vaccine Type
  • 13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 13.4.1. Solvent Detergent Method
    • 13.4.2. Radiation Method
    • 13.4.3. pH Concentration
    • 13.4.4. Others (Heat Inactivation, etc.)
  • 13.5. Market Attractiveness, by Method of Inactivation
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Subcutaneous
    • 13.6.3. Intravenous
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Homecare Settings
    • 13.8.4. Others (Research Centers, etc.)
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Vaccine Type
    • 13.11.2. By Method of Inactivation
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Inactivated Vaccines Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 14.2.1. Viral Vaccine
    • 14.2.2. Bacterial Vaccine
  • 14.3. Market Attractiveness, by Vaccine Type
  • 14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 14.4.1. Solvent Detergent Method
    • 14.4.2. Radiation Method
    • 14.4.3. pH Concentration
    • 14.4.4. Others (Heat Inactivation, etc.)
  • 14.5. Market Attractiveness, by Method of Inactivation
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Subcutaneous
    • 14.6.3. Intravenous
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Homecare Settings
    • 14.8.4. Others (Research Centers, etc.)
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Vaccine Type
    • 14.11.2. By Method of Inactivation
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 15.2.1. Viral Vaccine
    • 15.2.2. Bacterial Vaccine
  • 15.3. Market Attractiveness, by Vaccine Type
  • 15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 15.4.1. Solvent Detergent Method
    • 15.4.2. Radiation Method
    • 15.4.3. pH Concentration
    • 15.4.4. Others (Heat Inactivation, etc.)
  • 15.5. Market Attractiveness, by Method of Inactivation
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Subcutaneous
    • 15.6.3. Intravenous
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Homecare Settings
    • 15.8.4. Others (Research Centers, etc.)
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Vaccine Type
    • 15.11.2. By Method of Inactivation
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. GSK plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Mylan N.V.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Sanofi S.A.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Boehringer Ingelheim International GmbH
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. F. Hoffmann-La Roche AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bristol-Myers Squibb Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Bharat Biotech
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Serum Institute of India
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. INOVIO Pharmaceuticals, Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 02: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 03: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 08: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 09: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 13: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 14: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 18: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 19: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 23: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 24: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 28: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 29: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Inactivated Vaccines Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Inactivated Vaccines Market Revenue (US$ Bn), by Vaccine Type, 2023
  • Figure 03: Global Inactivated Vaccines Market Value Share, by Vaccine Type, 2023
  • Figure 04: Global Inactivated Vaccines Market Revenue (US$ Bn), by Method of Inactivation, 2023
  • Figure 05: Global Inactivated Vaccines Market Value Share, by Method of Inactivation, 2023
  • Figure 06: Global Inactivated Vaccines Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 07: Global Inactivated Vaccines Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 09: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 10: Global Inactivated Vaccines Market Value Share, by Region, 2023
  • Figure 11: Global Inactivated Vaccines Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 13: Global Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 14: Global Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 15: Global Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 16: Global Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 20: Global Inactivated Vaccines Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Inactivated Vaccines Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Inactivated Vaccines Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Inactivated Vaccines Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 26: North America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 27: North America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 30: North America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 31: North America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 37: Europe Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 38: Europe Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 41: Europe Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 42: Europe Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 48: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 49: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 52: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 53: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 59: Latin America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 60: Latin America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 63: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 64: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 70: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 71: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 74: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 75: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034